SavedAdd your journal

Journals / Çocuk Dergisi / 2017 / Cilt: 17 - Sayı: 4

Subcutaneous Immunoglobulin Use in Children

Çocuklarda Subkutan İmmünglobülin Kullanımı

Manolya ACAR
Ayper SOMER
Pages
146–150
Publication Date
2017-10-01
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Up-to-date information regarding SCIG use in pediatric patients is being summarized in this review

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Human plasma derived immunoglobulin products have been considered among treatment options for many of the disor- ders, particularly primary immune deficiencies.
📊
Key Findings & Data:In recent years, SCIG use has been preferred increasingly because of higher patient comfort, with decreased systemic side effects and costs.
💡
Conclusion & Impact:Up-to-date information regarding SCIG use in pediatric patients is being summarized in this review
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Subkutan immünglobülin · çocuk · tedavi

Abstract

Human plasma derived immunoglobulin products have been considered among treatment options for many of the disor- ders, particularly primary immune deficiencies. Immunoglobulins can be administered either intravenous IV , subcutaneous SC or intramuscular IM route. In recent years, SCIG use has been preferred increasingly because of higher patient comfort, with decreased systemic side effects and costs. Up-to-date information regarding SCIG use in pediatric patients is being summarized in this review

Özet

İnsan plazma kaynaklı immünglobülinler başta primer immün yetersizlik hastalıkları olmak üzere pek çok hastalı- ğın tedavi seçenekleri arasında yer almaktadır. İmmünglobülin preparatları; intravenöz IV , subkutan SC ya da intramüsküler IM yolla verilebilir. Son yıllar- da subkutan immünglobülin SIG uygulaması, hasta konfo- runun daha yüksek, maliyetinin ve yan etki insidansının daha düşük olması nedeniyle tercih edilmektedir. Bu yazıda çocuk hastalarda SIG kullanımı ile ilgili güncel bilgiler özetlenmiştir

🔖

Cite This Article

ACAR, M., SOMER, A. (2017). Subcutaneous Immunoglobulin Use in Children. Çocuk Dergisi, Cilt: 17 - Sayı: 4, 146–150. https://ajindex.com/articles/246847

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (8)

  1. Bruton oc. Agammaglobulinemia. Pediatrics 1952;9:722-8. Jolles S. Subcutaneous and intramuscular immune globulin therapy. www.uptodate.com. Janeway CA, Apt l, Gitlin D. Agammaglobulinemia. Trans Assoc Am Physicians 1953;66:200-2.
  2. Gitlin D, Janeway CA. Agammaglobulinemia: conge- nital, acquired and transient forms. Prog Hematol 1956;1:318-56.
  3. Hill lE, Mollison Pl. MRC working party on hypo- gammaglobulinemia, collection of cases and design of trial, Chap. II, Hypogammaglobulinemia in the UK. Her Majesty’s Stationery Office: London, 1971: pp. 4-8. Berger M. Subcutaneous administration of IgG. Immunol Allergy Clin North Am 2008;28:779. https://doi.org/10.1016/j.iac.2008.07.002 Stiehm ER. Adverse effects of human immunoglobu- lin therapy. Transfus Med Rev 2013;27:171. https://doi.org/10.1016/j.tmrv.2013.05.004 Berger M. Subcutaneous IgG in neurologic diseases. Immunotherapy 2014;6:71-83. https://doi.org/10.2217/imt.13.146
  4. Bourque PR, Pringle CE, Cameron W, Cowan J, Chardon JW. Subcutaneous immunoglobulin therapy in the chronic management of myasthenia gravis: A retrospective cohort study. PLoS One 2016;11: e0159993. https://doi.org/10.1371/journal.pone.0159993
  5. Misbah SA, Baumann A, Fazio R, Dacci P, Schmidt DS, Burton J, Sturzenegger M. A smooth transition protocol for patients with multifocal motor neuropathy going from intravenous to subcutaneous immunoglo- bulin therapy: an open-label proof-of-concept study. J Peripher Nerv Syst 2011;16:92-7. https://doi.org/10.1111/j.1529-8027.2011.00330.x US Food and Drug Administration (FDA) approval: http://www.fda.gov/biologicsbloodvaccines/bloodblo- odproducts/approvedproducts/licensedproductsblas/ fractionatedplasmaproducts/ucm414117.htm (Accessed on September 19, 2014).
  6. Hagan JB, Fasano MB, Spector S, et al. Efficacy and safety of a new 20% immunoglobulin preparation for subcutaneous administration, IgPro20, in patients with primary immunodeficiency. J Clin Immunol 2010; 30:734. https://doi.org/10.1007/s10875-010-9423-4
  7. Ochs HD, Gupta S, Kiessling P, et al. Safety and efficacy of self-administered subcutaneous immunog- lobulin in patients with primary immunodeficiency diseases. J Clin Immunol 2006;26:265. https://doi.org/10.1007/s10875-006-9021-7 Gardulf A. Immunoglobulin treatment for primary antibody deficiencies: advantages of the subcutaneous route. Bio Drugs 2007;21:105. https://doi.org/10.2165/00063030-200721020-00005
  8. Orange JS, Hossny EM, Weiler CR, et al. Use of intravenous immunoglobulin in human disease: a